HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients

Table 4

On treatment HOMA-IR, BMI, and serum leptin variations based on early viral decay (EVR versus non-EVR).

	EVR ()					Non-EVR ()
	Baseline		12 weeks		48 weeks	Baseline		12 weeks		48 weeks
HOMA-IR (median)	2.03 (0.3–5.6)		1.41 (0.33–3.35)		1.60 (0.42–4.18)	2.30 (0.4–10.5)	∧	2.18 (0.45–10.3)	∧	2.21 (0.81–9.23)
BMI (median)	22.9 (19.4–29.1)	∧	21.6 (19.4–29)	∧	21.9 (20–29.1)	24 (21.5–29.6)	∧	22.7 (20.3–29.1)	∧	22.6 (19.6–29)
Serum leptin (median)	10.5 (3.8–27.9)	∧	8.91 (3.3–39.6)	∧	12.6 (2.6–35.7)∖	10.15 (3–25.6)	∧	9.05 (3.8–25.7)	∧	9.70 (3.2–23.2)

(12 weeks versus baseline): ; (48 weeks versus baseline): ; (12 weeks versus baseline and 48 weeks versus baseline): = NS. EVR: early viral response.